Biomarkers of antiangiogenic therapy: how do we move from candidate biomarkers to valid biomarkers?

Editorial

Dan G Duda et al. J Clin Oncol. 2010.

. 2010 Jan 10;28(2):183-5.

doi: 10.1200/JCO.2009.24.8021. Epub 2009 Nov 30.

No abstract available

Comment on

Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.
Lockhart AC, Rothenberg ML, Dupont J, Cooper W, Chevalier P, Sternas L, Buzenet G, Koehler E, Sosman JA, Schwartz LH, Gultekin DH, Koutcher JA, Donnelly EF, Andal R, Dancy I, Spriggs DR, Tew WP. Lockhart AC, et al. J Clin Oncol. 2010 Jan 10;28(2):207-14. doi: 10.1200/JCO.2009.22.9237. Epub 2009 Nov 30. J Clin Oncol. 2010. PMID: 19949018 Free PMC article. Clinical Trial.
Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.
Hanrahan EO, Lin HY, Kim ES, Yan S, Du DZ, McKee KS, Tran HT, Lee JJ, Ryan AJ, Langmuir P, Johnson BE, Heymach JV. Hanrahan EO, et al. J Clin Oncol. 2010 Jan 10;28(2):193-201. doi: 10.1200/JCO.2009.22.4279. Epub 2009 Nov 30. J Clin Oncol. 2010. PMID: 19949019 Free PMC article. Clinical Trial.